Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent primary serous peritoneal carcinoma: An initial report

Gynecologic Oncology

Volumn 77, Issue 1, 2000, Pages 44-47

  Wang, Peng Hui ^a   Liu, Ren Shyan ^a   Li, Ywan Feng ^a   Ng, Heung Tat ^a   Yuan, Chiou Chung ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Positron emission tomography; Recurrent primary serous peritoneal carcinoma

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ARTICLE; CARCINOMATOUS PERITONITIS; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTADENOCARCINOMA; DIAGNOSTIC ACCURACY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 0034051491     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5738     Document Type: Article

References (25)

1. Stafford-Johnson D B, Bree R L, Francis I R, Korobkin M. CT appearance of primary papillary serous carcinoma of the peritoneum. A J R. 171:1998;687-689.
2. Furukawa T, Ueda J, Takahashi S, Higashino K, Shimura K, Tsujimura T, Araki Y. Peritoneal serous papillary carcinoma: radiological appearance. Abdominal Imaging. 24:1999;78-81.
3. Kaplan B Y, Hawkins R, Hoh C, Lee M, Tse N, Cane P, Glaspy I. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol. 51:1993;175-181.
4. Glaspy J A, Hawkins R A, Hoh C K, Phelps M E. Use of positron emission tomography in oncology. Oncology. 7:1993;41-46.
5. Bloss J D, Liao S Y, Buller R E, Manetta A, Berman M L, Mcmeekin S, Bloss L P, DiSaia P J. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 50:1993;347-351.
6. Eltabbakh G H, Werness B A, Piver S, Blumenson L E. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol. 71:1998;230-239.
7. Nicklin J L, Copeland L J, Luesley D M, Kehoe S. Secondary-look surgery. Gershenson D M, McGuire W P. Ovarian Cancer. 1998;85-100 Churchill Livingstone, New York.
8. Di Chiro G, De la Paz R L, Brooks R A, Sokoloff L, Kornblith P L, Smith B H, Patronas N J, Kufta C V, Kessler R M, Johnston G S, Manning R G, Wolf A P. Glucose utilization of cerebral gliomas measured by 18F-fluorodeoxyglucose and PET. Neurology. 32:1982;1323-1329.
9. Di Chiro G. Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors - a powerful diagnostic and prognostic tool. Invest Radiol. 22:1987;360-371.
10. Sisson J C, Ackermann R J, Meyer M A, Wahl R L. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab. 77:1993;1090-1094.
11. Seltzer M A, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps M E, Gambhir S S, Hoh C K. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 162:1999;1322-1328.
12. Hoh C K, Schieper C. 18-FDG imaging in breast cancer. Semin Nucl Med. 29:1999;49-56.
13. Hoh C K, Glasp Y J, Rosen P, Dahlbom M, Lee S J, Kunkel L, Hawkin R A, Maddahi J, Phelps M E. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 38:1997;343-348.
14. Gupta N C, Frank A R, Dewan N A, Redepenning L S, Rothberg M L, Majlliard J A, Phalen J J, Sunderland J J, Frick M P. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 184:1992;441-444.
15. Rege S, Maass A, Chaiken L, Hoh C K, Choi Y, Lufkin R, Anzai Y, Juillard G, Maddahi J, Phelps M E. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancer. Cancer. 73:1994;3047-3058.
16. Schlag P, Lehner B, Strauss L G, Georgi P, Herfarth C. Scar or recurrence rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg. 124:1989;197-200.
17. Yuan C C, Liu R S, Wang P H, Ng H T, Yeh S H. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma: an initial report. J Reprod Med. 44:1999;775-778.
18. Casey M J, Gupta N C, Muths C K. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol. 53:1994;331-338.
19. Hubner K F, McDonald T W, Niethammer J G, Smith G T, Gould H R, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography using 2-(18F) deoxyglucose (2-(18F)FDG). Gynecol Oncol. 51:1993;197-204.
20. Kaplan B Y, Hoh C, Tse N, Futoran R, Hawkins R, Glaspy I. Whole-body positron emission tomography with fluoro-18F-2-deoxyglucose can detect recurrent metastatic carcinoma of the fallopian tube. Gynecol Oncol. 49:1993;383-388.
21. Adler L P, Blair H F, Makley J T, Williams R P, Joyce M J, Leisure G, al-Kaisi N, Miraldi F. Noninvasive grading of musculo-skeletal tumors using PET. J Nucl Med. 32:1991;1508-1512.
22. Hoh C K, Schiepers C, Seltzer M A, Cambhir S S, Silverman D H, Czernin J, Maddahi J, Phelps M E. PET in oncology: will it replace the other modalities? Semin Nucl Med. 27:1997;94-106.
23. Biersack H J, Bender H, Ruhlmann J, Schomburg A, Grunwald F. FDG-PET in clinical oncology: review and evaluation of results of a private clinical PET center. Freeman L M. Nuclear Medicine Annual 1997. 1997;1-30 Lippincott-Raven, Philadelphia.
24. Warburg O. On the origin of cancer cells. Science. 123:1956;309-314.
25. Shilds A F, Graham M M, Spence A M. The role of PET imaging in clinical oncology - a current status report. Freeman L M. Nuclear Medicine Annual 1995. 1995;129-168 Lippincott-Raven, New York.